New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'
By
The Conversation
Pure flour-power. Hearty enough to carry you through lunch.
Summary
Pancreatic cancer has an extremely low survival rate (97% mortality within 5 years for metastatic cases) due to late detection and the formation of a 'fibrotic fortress' that shields tumors from chemotherapy. The article discusses a potential breakthrough drug that has achieved what was previously considered impossible in treating this aggressive cancer, offering new hope for patients who currently have very limited treatment options.
Key quotes
· 3 pulledFor patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis.
Pancreatic cancer is so deadly in part because there are no effective screening tests, and it rarely causes noticeable symptoms in its earliest stages.
The tumors form a 'fibrotic fortress' that shields them from traditional chemotherapy drugs.
You might also wanna read
Promising pancreatic cancer drug may unlock new class of treatments targeting cancer's master switch
The article discusses a promising new drug that targets pancreatic tumors and may have revealed a "master switch" for cancer. The treatment
economist.com·1h ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·4mo ago
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·12d ago